Introduction {#s1}
============

Glutamate, the major excitatory neurotransmitter in the brain, has been implicated in many neurological and psychiatric disorders (Fonnum, [@B11]). This amino acid is present in all cell types and participates in numerous cellular functions, from protein biosynthesis to various aspects of metabolism. As a *bona fide* neurotransmitter, glutamate must first be uploaded into synaptic vesicles within presynaptic terminals before undergoing regulated release at the synaptic cleft (Fonnum et al., [@B12]; Gasnier, [@B17]). Proton-dependent carriers, named vesicular glutamate transporters (VGLUTs) 1--3, are responsible for the vesicular accumulation of glutamate (for review see El Mestikawy et al., [@B9]; Hnasko and Edwards, [@B24]). These key actors of excitatory neurotransmission were first identified and characterized in rodents and humans (Ni et al., [@B33]; Bellocchio et al., [@B3], [@B4]; Aihara et al., [@B1]; Takamori et al., [@B43], [@B44], [@B42]; Fremeau et al., [@B15], [@B13]; Gras et al., [@B19]; Schafer et al., [@B38]; Varoqui et al., [@B48]). Takamori and colleagues established more than a decade ago that the expression of a vesicular glutamate transporter in neurons was sufficient to confer a "glutamatergic phenotype" (Takamori et al., [@B43], [@B44]). Moreover, alteration of VGLUT levels has been shown to modify the glutamate content of synaptic vesicles and hence the strength of excitatory synaptic transmission (Daniels et al., [@B7]). VGLUTs are thus key anatomical and functional markers of glutamatergic transmission.

With the advent of genetically engineered mice, specific features and functions of the 3 VGLUTs have recently been identified (for review see Wallen-Mackenzie et al., [@B50]). VGLUT1-knockout mice (VGLUT1-KO) die after weaning (Fremeau et al., [@B16]; Wojcik et al., [@B51]) while VGLUT2-KO die immediately after birth from respiratory insufficiency (Moechars et al., [@B32]; Wallen-Mackenzie et al., [@B49]). These findings have clearly established that VGLUT1 and VGLUT2 are engaged in the regulation of vital functions. In contrast, VGLUT3-KO mice have a normal life expectancy despite being deaf and developing anxiety and discrete basal locomotor phenotypes (Ruel et al., [@B37]; Seal et al., [@B39]; Amilhon et al., [@B2]). Recent studies using constitutive or conditional knock-out mouse models have further established that the 3 VGLUTs are involved in cognition, mood regulation, locomotor activity, reward, and pain (for reviews, see Seal and Edwards, [@B40]; Benarroch, [@B5]; Wallen-Mackenzie et al., [@B50]; El Mestikawy et al., [@B9]).

The anatomical distribution of the 3 VGLUTs has been thoroughly characterized in the mature rodent brain (for review see El Mestikawy et al., [@B9]). To briefly summarize, a large population of cortical excitatory neurons expresses VGLUT1, whereas subcortical glutamatergic neurons express VGLUT2 (Aihara et al., [@B1]; Herzog et al., [@B21]). In addition, VGLUT2 is also found in some cortical neurons (predominantly layer IV) while VGLUT1 is expressed in some thalamic nuclei (Fremeau et al., [@B15]). Together, VGLUT1- and VGLUT2-expressing neurons represent the bulk of "canonical" glutamatergic neurons in the brain. VGLUT1 represents the major subtype and accounts for approximately 80% of total vesicular transport of glutamate in the brain (Fremeau et al., [@B16]). Combined, VGLUT1- and VGLUT2-immunoreactive (-IR) neurons extend nearly ubiquitous projections throughout the brain. In contrast, the distribution of VGLUT3-immunoreactivity is much more discrete, as it is found in discrete population of neurons using other transmitters than glutamate (Fremeau et al., [@B13]; Gras et al., [@B19]; Schafer et al., [@B38]; Takamori et al., [@B42]). VGLUT3 is expressed by cholinergic interneurons in the dorsal and ventral striatum, subpopulations of GABAergic basket cells in the cortex and hippocampus, and serotoninergic neurons (for review, see El Mestikawy et al., [@B9]). However, It should be kept in mind that VGLUT1 and VGLUT2 as well are expressed by "non-glutamatergic" neurons (Boulland et al., [@B6]; Fattorini et al., [@B10]; Zander et al., [@B52]; Ren et al., [@B36]).

The almost non-overlapping distribution of the 3 VGLUTs delineates three complementary glutamatergic systems. VGLUT1 and VGLUT2 play major neurophysiological roles in virtually all major neuronal circuits, while VGLUT3 is involved in more subtle modulation of local transmission (for review see El Mestikawy et al., [@B9]).

The widespread distributions of VGLUT1-3 in rodent CNS suggest their involvement in the regulation of sensori-motor, cognitive and mood processes. Hence, it can be surmised that alterations in the expression of these proteins may underlie significant aspects of human neurolopathologies. Indeed, recent postmortem studies have highlighted alterations in VGLUT1 and VGLUT2 expression in mood disorders and psychosis (Oni-Orisan et al., [@B35]; Uezato et al., [@B46]; Eastwood and Harrison, [@B8]) as well as in neurological disorders such as Parkinson disease, Alzheimer disease and epilepsy (Kirvell et al., [@B28]; Kashani et al., [@B26], [@B27]; Van Der Hel et al., [@B47]). These studies measured VGLUT1-3 mRNA or VGLUT1 and VGLUT2 protein in cortical or subcortical areas. Unfortunately, the significance of such results is limited by the fact that our current anatomical knowledge of VGLUT-defined glutamatergic subsystems in the human brain is partial at best. The aim of the present study was thus to characterize the distributions of VGLUT1-3 transcripts and proteins in major regions of the human brain.

Materials and methods {#s2}
=====================

Human brain samples
-------------------

This study was approved by the Douglas Institute Research Ethics Board, and written informed consent from next-of-kin was obtained in each case. Postmortem brain samples from six caucasian individuals (Table [1](#T1){ref-type="table"}) were provided by the Douglas-Bell Canada Brain Bank ([www.douglasbrainbank.ca](http://www.douglasbrainbank.ca)). Three of the individuals died from accidents or natural causes, with one having been diagnosed with major depression and two who had no history of neurological nor psychiatric illness. The two other individuals committed suicide during a depressive episode (Table [1](#T1){ref-type="table"}). After extraction, brains were immediately placed at 4°C, rapidly sent to the Douglas-Bell Canada Brain Bank where they were sliced into thick sections, rapidly frozen and stored at −80°C until further use. The postmortem refrigeration delay, i.e., the time between death and storage of the body at 4°C at the morgue, was of 15.5 ± 8.6 h (±SEM) on average. Frozen samples from the following brain regions were dissected from the left hemisphere by expert brain bank staff, cut on a cryostat in 10 μm-thick serial sections, and processed for *in situ* hybridization or immunoautoradiography (IAR), as detailed below: cerebral cortex (Brodmann areas \[BAs\] 4 and 9), hippocampus, striatum, amygdala, cerebellum, substantia nigra, thalamus, raphe.

###### 

**Subject information**.

  **Subject**   **Gender**   **Age (years)**   **Diagnosis**   **Cause of death**                                              **RD (h)**
  ------------- ------------ ----------------- --------------- --------------------------------------------------------------- ------------
  135           Male         18                Nil             Natural death cardiovascular[^\*^](#TN1){ref-type="table-fn"}   2.0
  138           Female       66                Nil             Car accident[^\*^](#TN1){ref-type="table-fn"}                   57.6
  146           Male         26                SCZ             Suicide[^\*^](#TN1){ref-type="table-fn"}                        3.9
  152           Female       49                MDD             Suicide[^\*^](#TN1){ref-type="table-fn"}                        14.7
  155           Male         31                MDD             Natural death cause unknown[^\*^](#TN1){ref-type="table-fn"}    9.2
  513           Male         72                Nil             Heart attack                                                    5.0

*As recorded by the coroner. MDD, major depressive disorder; Nil, no psychiatric nor neurological disorders; RD, refrigeration delay; SCZ, schizophrenia*.

*In situ* hybridization
-----------------------

*In situ* hybridization was performed as recommended by Oramacell (Paris, France) and as previously reported (Gras et al., [@B18]). In brief, sense or antisense oligonucleotides specific for human VGLUT1, VGLUT2, or VGLUT3, the dopamine (DAT) or serotonin (SERT) transporters (**Table 3**) (generated by Oramacell) were labeled with \[^35^S\]-dATP (GE Healthcare) using terminal deoxynucleotidyl transferase (GE Healthcare) to a specific activity of 1--3 × 10^8^ dpm/mg. On the day of the experiment, fresh frozen section (10 μm) were fixed in 3.7% formaldehyde in phosphate-buffered saline (PBS), washed with PBS, rinsed with water, dehydrated in 50 and 70% ethanol, and air-dried. Sections were then covered with 140 μl of hybridization medium (Oramacell, Paris, France) containing 1.4 μl of the labeled oligonucleotide. Slides were incubated 16 h at 42°C, washed 2 × 15 min in saline sodium citrate buffer (SSC 1X) and dithiothreitol (DTT, 10 mM) at 53°C, 2 × 15 min in SSC 0.5X, dehydrated in ethanol, air-dried and exposed to a BAS-SR Fujifilm Imaging Plate for 7--10 days for VGLUT1 and VGLUT2, 21 days for VGLUT3, 14 days for the dopamine transporter (DAT) and for 4 days for the serotonin transporter (SERT) mRNA. The plates were scanned with a Fujifilm BioImaging Analyser BAS-5000. Each marker was investigated with a combination of 4--5 antisense or sense oligonucleotides (Table [2](#T2){ref-type="table"}). In preliminary experiments, each antisense or sense oligonucleotide was incubated individually or as pool of sense or antisense nucleotides for a given marker. A labeling was considered specific when: (i) the distribution observed for each individual oligonuleotide were similar as the one obtained with combined 4 oligonucleotides and (ii) no labeling was obtained with corresponding sense nucleotides.

###### 

**List of oligonucleotides used for *in situ* hybridization**.

  --------------------------------------------------
  **HUMAN VGLUT1**
  **Antisense oligonucleotides**
  HV1-AS1: GGGACTCGTAGGAGACGAGCAGCCAGAACAGGTAC
  HV1-AS2: GAGAGCACGACCCGCTAGCTTCCGAAACTCCTCCT
  HV1-AS3: GAGCAGGGTTCCTTGACACTGTCACTCAGGCCAG
  HV1-AS4: CCCCGTAGAAGATGACACCTCCATAGTGCACCAGGG
  **Sense oligonucleotides**
  HV1-S1: GTACCTGTTCTGGCTGCTCGTCTCCTACGAGTCCC
  HV1-S2: AGGAGGAGTTTCGGAAGCTAGCGGGTCGTGCTCTC
  HV1-S3: CTGGCCTGAGTGACAGTGTCAAGGAACCCTGCTC
  HV1-S4: CCCTGGTGCACTATGGAGGTGTCATCTTCTACGGGG
  **HUMAN VGLUT2**
  **Antisense oligonucleotides**
  HV2-AS1: GCTTCTTCTCCAGACCCCTGTAGATCTGGCCGAG
  HV2-AS2: GAAGGGGAGTATCCGGTGGCAAAGAGCGCAAGCAG
  HV2-AS3: CCCCAAAAGAAGGAACCGTGGATCATCCCCACGG
  HV2-AS4: CTTTCTCCTTGATGACCTTGCCCCCGCGGTGGAT
  **Sense oligonucleotides**
  HV2-S1: CTCGGCCAGATCTACAGGGTGCTGGAGAAGAAGC
  HV2-S2: CTGCTTGCGCTCTTTGCCACCGGATACTCCCCTTC
  HV2-S3: CCGTGGGGATGATCCACGGTTCCTTCTTTTGGGG
  HV2-S4: ATCCACCGCGGGGGCAAGGTCATCAAGGAGAAAG
  **HUMAN VGLUT3**
  **Antisense oligonucleotides**
  HV3-AS1: CGGCTTCTCTCCAAAGGTGGTGCCCACTTA
  HV3-AS2: AGCCAACCACCAGGAGTAAGGTTGCCTCCATGCC
  HV3-AS3: CCCCTCCCAATATTTGGACCTCTGGCAAGCTGGG
  HV3-AS4: GGACCATCCAATGTACTGCACCAACACCCCAGCC
  **Sense oligonucleotides**
  HV3-S1: GGAGTAAGTGGGCACCACCTTTGAGAGAAGCCG
  HV3-S2: GGCATGGAGGCAACCTTACTCCTGGTGGTTGGCT
  HV3-S3: CCCAGCTTGCCAGAGGTCCAAATATTGGGAGGGG
  HV3-S4: GGCTGGGGTGTTGGTGCAGTACATTGGATGGTCC
  **HUMAN DAT**
  **Antisense oligonucleotides**
  DAT1AS1: GACTTCCTGGGGTCTTCGTCTCTGCTCCCTCTAC
  DATAS2: GTAGGCCAGTTTCTCTCGAAAGGACCCAGGCAGG
  DATAS3: GGTATGCTCTGATGCCGTCTATGGCTCCAGGGAG
  DATAS4: GCCTGAGTGGCAGTAGCCTGAGCTGGTTTCAAGG
  DATAS5: GTTGGCCCAGTCGGGGAAGATGTAGGCTCCGTAGT
  **Sense oligonucleotides**
  DAT1S1: GTAGAGGGAGCAGAGACGAAGACCCCAGGAAGTC
  DATS2: CCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTAC
  DATS3: CTCCCTGGAGCCATAGACGGCATCAGAGCATACC
  DATS4: CCTTGAAACCAGCTCAGGCTACTGCCACTCAGGC
  DATS5: ACTACGGAGCCTACATCTTCCCCGACTGGGCCAAC
  **HUMAN SERT**
  **Antisense oligonucleotides**
  humSERT-AS1: AGCCACTAGGGTGGTGGTGGTCGCTGGGATAGAGT
  humSERT-AS2: CCTCCGAGCTCTCTATCGTCGGGATTGACACGTC
  humSERT-AS3: CAGGACCCCAAAGCCCGGACCAAGAGAGAAGAAG
  humSERT-AS4: GAACAGGAGAAACAGAGGGCTGATGGCCACCCAG
  **Sense oligonucleotides**
  humSERT-S1: ACTCTATCCCAGCGACCACCACCACCCTAGTGGCT
  humSERT-S2: GACGTGTCAATCCCGACGATAGAGAGCTCGGAGG
  humSERT-S3: CTTCTTCTCTCTTGGTCCGGGCTTTGGGGTCCTG
  humSERT-S4: CTGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTC
  --------------------------------------------------

Immunoautoradiography
---------------------

To visualize proteins, immunoautoradiography (IAR) was performed as previously described (Kashani et al., [@B26], [@B27]). Selective antibodies against VGLUT1 and VGLUT2 were obtained by immunization of rabbits with the corresponding peptides, as described previously (Herzog et al., [@B21]; Kashani et al., [@B26], [@B27]). To detect VGLUT3 in human samples an antiserum was developed by immunizing rabbits with the N-CEEIELNHESFASPKKKM-C peptide fused to the Keyhole limpet haemocyanin (AgroBio, Villeny, France, <http://www.agro-bio.fr/>). The anti-VGLUT3 antiserum was affinity purified on an Affigel-10 (Biorad, Richmond, CA) matrix coupled to the N-CEEIELNHESFASPKKKM-C peptide as described (Kashani et al., [@B26]). The specificity of the newly developed serum was assessed by comparing the distribution of VGLUT3-positive immunolabeling obtained with the serum newly produced against a human peptide (in rabbit) and a previously validated rodent anti-VGLUT3 (in guinea pig, Gras et al., [@B18]; Amilhon et al., [@B2]; Miot et al., [@B31]). Immunofluorescence experiments were conducted as previously described on wildtype or VGLUT3-nul mouse brain (Figure [1](#F1){ref-type="fig"}; Gras et al., [@B18]; Amilhon et al., [@B2]; Miot et al., [@B31]). As shown in Figures [1A--C,E--G,I--K](#F1){ref-type="fig"} the immunodistribution of the new anti-human VGLUT3 antiserum overlapped with the known labeling of VGLUT3 in both mouse hippocampus and striatum. Furthermore, no labeling was observed with the new anti-human VGLUT3 antiserum on sections of mouse brain that no longer expressed VGLUT3 (Figures [1D,H,L](#F1){ref-type="fig"}; Gras et al., [@B18]). This experiment demonstrated that the new serum binds to VGLUT3 and rules out cross-reactivity with VGLUT1 and VGLUT2 or any other brain protein.

![**Specificity of the newly developed anti-human VGLUT3 antiserum**. The distribution of VGLUT3-positive immunolabeling was compared between the purified serum newly produced in rabbit against a human peptide **(A,E,I)** and a previously validated rodent anti-VGLUT3 in guinea pig **(B,F,J)**, (Gras et al., [@B18]; Amilhon et al., [@B2]; Miot et al., [@B31]). Immunofluorescence experiments were conducted as previously described (Gras et al., [@B18]; Amilhon et al., [@B2]; Miot et al., [@B31]) on sections taken at the level of the striatum **(A--D)** or hippocampus **(E--L)** of wild-type **(A--C,E--G,I--K)** or VGLUT3-null mice **(D,H,L)**. The newly developed anti-human VGLUT3 was visualized with red fluorescence (anti rabbit IgG-Alexa fluor 555) and the rodent isoform with green fluorescence (anti-guinea pig IgG-Alexa fluor 488). The merged channels are shown in **(C)** for the caudate-putamen and in **(G,K)** for the hippocampus. Scale bar (in **L**): 100 μm in **(A--D)**, 30 μm in **(E--H)**, and 10 μm in **(I--L)**. Abbreviations: CA3, CA3 field of the pyramidal layer of the hippocampus; cc, corpus callosum; CPu, caudate putamen; Cx, cerebral cortex.](fnana-09-00023-g0001){#F1}

Anti-VGLUT1 was used at 1:2000; anti-VGLUT2 affinity purified antiserum at 1:4000 (Kashani et al., [@B26], [@B27]) and the affinity purified anti-VGLUT3 at 1:4000.

On the day of the experiment, fresh frozen sections (10 μm) were fixed in 4% formaldehyde in PBS, washed with PBS, and preincubated in PBS containing 3% bovine serum albumin, 1% normal goat serum and 1 mM NaI (buffer A) for 1 h. Sections were incubated with buffer A supplemented with polyclonal rabbit anti-VGLUT1-3 antisera overnight at 4°C, followed by anti-rabbit \[^125^I\]-IgG (GE Healthcare lifesciences, 100 mCi/ml) for 2 h. Sections were exposed to X-ray films (Biomax MR, Kodak, France) for 24 h, and images were digitized using a PowerLook 100 Umax scanner and analyzed with Multi Gauge Software.

Immunohistochemistry
--------------------

Immunohistochemistry detection of VGLUT1-3 on human brain sections was performed as previously described with minor modifications. Paraffin embedded sections (5 μm) of the cerebellum were obtained from formalin-fixed brains as already described (Torres-Platas et al., [@B45]). VGLUT1-3 immunostaining was performed with the anti-VGLUT1 antiserum (1:500 dilution) as described previously (Kashani et al., [@B27]) and then processed with biotinylated goat anti-rabbit IgG (1:500 dilution), streptavidine (1:1000 dilution) and 3′3-diaminobenzidine reagents (Jackson Immunoresearch, Brulington Ontario, Canada). Images were obtained with a Zeiss Axioscop microscope.

Results {#s3}
=======

General considerations
----------------------

The overall regional distributions of VGLUT1-3 mRNA and proteins were highly similar between subjects (Table [3](#T3){ref-type="table"}), and only slight inter-individual variability in the intensity of signals was noticed, irrespective of gender, age, presence/absence of psychiatric disorder, or cause of death.

###### 

**Distribution of VGLUT1-3 transcripts and proteins in various area of the human brain**.

  **Transporter**   **VGLUT1**   **VGLUT2**   **VGLUT3**   **Subject**                 
  ----------------- ------------ ------------ ------------ ------------- ------ ------ --------------------
  Cerebral cortex   +++          +++          \+           ++            \+     ++     146
  Hippocampus       +++          +++          N.D.         ++            \+     +++    146 (**Figure 3**)
                                                                                       155 (**Figure 4**)
  Amygdala          \+ (LA)      +++          N.D.         ++            N.D.   ++     135
  Basal Ganglia     N.D.         +++          N.D.         +++           \+     +++    152
                                                                                       155
  Habenula          N.D.         \+           +++          +++           N.D.   +++    146
  SNC               N.D.         \+           N.D.         +++           N.D.   +++    
  Thalamus          N.D.         ++           +++          ++            N.D.   N.D.   138
  Raphe             ++ (Pons)    ++           +++ (Pons)   +++           ++     +++    146
  Cerebellum        +++ (Gcl)    +++          N.D.         +++           N.D.   N.D.   146

*LA, lateral amygdala; Gcl, granular cell layer of the cerebellum; N.D., not detected*.

Regional VGLUT1-3 mRNA and protein distributions
------------------------------------------------

### Cerebral cortex (BA4, BA9)

The expression patterns of each of the three VGLUTs were conserved in both motor (BA4) and prefrontal associative cortex (BA9) (Figure [2](#F2){ref-type="fig"}). VGLUT1 mRNA was absent in upper layers but abundant in layers V--VI, with varying intensity levels. Sparse labeling was also occasionally observed in the underlying white matter. VGLUT1 protein detected by IAR was strongly and homogeneously distributed throughout the cortical thickness, but absent in white matter.

![**Distribution of VGLUT1-3 mRNA and protein in cerebral cortical Brodmann areas (BA)4 and BA9**. Boxed regions are enlarged and shown in negative.](fnana-09-00023-g0002){#F2}

VGLUT2 mRNA was restricted to a band of cells spanning lower layer V. This distribution was mirrored by the presence of a more abundant cortical VGLUT2-immunoreactive material in layer V. The other cortical layers were uniformly immunoreactive but less intensely than layer V. In contrast to VGLUT1 and VGLUT2, VGLUT3 mRNA was only observed in scarce cells across the gray matter. VGLUT3 protein, however, was observed throughout the cortex with particular abundance in upper and lower layers, above and below of a band of lower intensity in mid-cortex.

### Hippocampus

In the hippocampal formation, VGLUT1 mRNA was detected in the pyramidal layer of Cornu Ammonis (CA1-3) fields, in the granule cell layer of the dentate gyrus (DG), as well as in sparse cells across the hilus (Figure [3](#F3){ref-type="fig"}). Weak levels of transcripts were observed in the presubiculum. VGLUT1 protein was much more widely distributed, with strong immunoreactivity observed throughout gray matter, except in the granule cell layer of the DG and in white matter tract of the stratum lacunosam molecular above the molecular layer of the DG.

![**Distribution of VGLUT1-3 mRNA and protein in the hippocampal formation**. Boxed regions are enlarged and shown in negative. Abbreviations: CA1--3, fields of the pyramidal layer of the hippocampus; DG, dentate gyrus; Hil, hilus of the dentate gyrus; mol DG, molecular layer of the dentate gyrus; PHG, parahippocampal gyrus; S, subiculum.](fnana-09-00023-g0003){#F3}

Although VGLUT2 mRNA was not detected in the hippocampus, the protein was very strongly expressed in the molecular layer of the DG, as well as in the mossy fiber pathway and in the subiculum.

VGLUT3 mRNA was only expressed in scattered cells throughout the hippocampal formation, except within the CA pyramidal cell layer and granule cell layer of the DG. The pattern of VGLUT3-IR was radically different, with more widespread distribution in gray matter displaying particularly strong signal in the outer DG granule cell layer, hilus, and mossy fiber pathway.

These patterns of expression were observed at various levels of the anteroposterior axis of the hippocampus (Figure [4](#F4){ref-type="fig"}).

![**Distribution of VGLUT1-3 proteins at various levels of the antero-posterior axis of the hippocampus**. Sections immunolabeled for VGLUT1, VGLUT2, and VGLUT3 were obtained at anatomical levels corresponding approximately to etched lines I-IV. Abbreviations: CA1--3, fields of the pyramidal layer of the hippocampus; DG, dentate gyrus; Ent, entorhinal cortex; FuG, fusiform gyrus; Hil, hilus; MolDG, molecular layer of the dentate gyrus; PaS, parasubiculum; PRC, perirhinal cortex; PrS, presubiculum; S, subiculum.](fnana-09-00023-g0004){#F4}

### Amygdala

Of the three transporters examined, VGLUT1 was the only one to display mRNA expression in the amygdala, with very faint signal being mostly restricted to the lateral amygdala. In contrast, all three VGLUT proteins were labeled in the amygdala. Immunoreactivities were prominent in the basolateral complex, although VGLUT3-IR was weaker than VGLUT1- and VGLUT2-IR (Figure [5](#F5){ref-type="fig"}).

![**Distribution of VGLUT1-3 mRNA and protein in the amygdala**. In addition to the in HIS and immunoautoradiographic labeling, the histological staining of an adjacent section is shown on the left. Abbreviation: LA, lateral amygdala.](fnana-09-00023-g0005){#F5}

### Basal ganglia

VGLUT1 and VGLUT2 transcripts were absent from basal ganglia whereas VGLUT3 mRNA was detected in sparse cells distributed in the caudate the putamen and the nucleus accumbens (Figure [6](#F6){ref-type="fig"}). Immunoreactivity was abundant for all three VGLUT proteins in the caudate, putamen, and nucleus accumbens. In the globus pallidus, VGLUT1-IR was absent, whereas VGLUT2 and VGLUT3 were weakly expressed in both external and internal segments. These patterns of expression were observed throughout the anteroposterior axis.

![**Distribution of VGLUT1-3 mRNA and protein in the caudate-putamen region**. Boxed regions are enlarged and shown in negative. Abbreviations: Ac, nucleus accumbens; Cd, caudate nucleus; EGP, external globus pallidus; GP, globus pallidus; ic, internal capsule; IGP, internal globus pallidus; LH, lateral hypothalamus; lml, lateral medullary lamina of globus pallidus; Pu, putamen.](fnana-09-00023-g0006){#F6}

Dopaminergic cells from the substantia nigra *pars compacta* (SNC) were readily observed following *in situ* hybridization performed with antisense oligonucleotides targeting DAT (Figure [7](#F7){ref-type="fig"}). None of the 3 VGLUTs was found to display mRNA expression in adjacent sections of the substantia nigra. However, all three transporters presented diffuse IR with transporter-specific intensities. Thus, VGLUT1 and VGLUT3 displayed weak and strong immunoreactivities, respectively, whereas VGLUT2 presented intermediate labeling. The only labeling heterogeneity observed within this nucleus was for VGLUT3-IR, which seemed stronger in the SN pars medialis (Figure [7](#F7){ref-type="fig"}).

![**Distribution of VGLUT1-3 mRNA and protein in substantia nigra**. Substantia nigra *pars compacta* (SNC) was identified by detection of the transcript coding for the dopamine transporter (DAT). Abbreviations: fr, fasciculus retroflexus; lHb, lateral habenula; mHb, medial habenula; R, red nucleus.](fnana-09-00023-g0007){#F7}

### Habenula

The habenular complex displayed strong content of VGLUT2 mRNA transcripts, and absence of VGLUT1 and VGLUT3 mRNAs. All three VGLUT proteins were labeled in the habenula. VGLUT2-IR was very strong in both the lateral and medial habenula, VGLUT3-IR was high and moderate in the medial and lateral portions of the habenula, respectively, and faint VGLUT3-IR was restricted to the medial part of the complex (Figure [7](#F7){ref-type="fig"}). VGLUT2 mRNA was also observed in sparse cells located ventrally to the habenula.

### Thalamus

Of the three VGLUTs, only VGLUT2 mRNA was found to be expressed in the thalamus (Figure [8](#F8){ref-type="fig"}). It was mainly present in scattered cells in the ventral lateral posterior (VLP) nucleus as well as the in the ventral posterior lateral (VPL) nucleus. Moderate VGLUT2-IR was moderate in the VLP, but extended beyond the extent of transcript distribution. VGLUT2-IR was also observed, albeit more weakly, in the mediodorsal thalamic nucleus. Despite the absence of transcript in this region, VGLUT1 protein was clearly expressed in all thalamic nuclei in the sampled region, with the exception of the reticular nucleus. VGLUT1-IR was strongest in the mediodorsal nucleus. Very faint and diffuse VGLUT3-IR was detected in the thalamus, with no particular pattern of expression.

![**Distribution of VGLUT1-3 mRNA and protein in the thalamus**. Abbreviations: Cd, caudate nucleus; MD, mediodorsal thalamic nucleus; Rt, reticular thalamic nucleus; VLP, ventral lateral posterior thalamic nucleus; VPL, ventral posterior thalamic nucleus.](fnana-09-00023-g0008){#F8}

### Raphe

Serotonergic neurons were observed by SERT ISH in the raphe. This area (raphe dorsalis) was partially labeled by VGLUT3 ISH, but did not display VGLUT1 nor VGLUT2 mRNA (Figure [9](#F9){ref-type="fig"}). This indicates that VGLUT3 is expressed only in a subset of 5HT neurons, as previously described in rodents (Kiyasova et al., [@B29]). In the same sections, the pons was found to be strongly labeled by VGLUT1 and VGLUT2 ISH, whereas VGLUT3 ISH revealed a complete absence of transcript. In contrast, all three VGLUT proteins were distributed in the pons in a similar and overlapping fashion, but with varying degrees of intensity. Thus, VGLUT1 immunoreactivity was the strongest, followed by VGLUT3- and VGLUT2-immunoreactivity (Figure [9](#F9){ref-type="fig"}).

![**Distribution of VGLUT1-3 mRNA and protein in the raphe**. Serotoninergic cells in the dorsal raphe nucleus (DR) were identified by detection of the transcript coding for the serotonin transporter (SERT).](fnana-09-00023-g0009){#F9}

### Cerebellum

In the cerebellum, VGLUT1 mRNA was detected only in the granule cell layer (Figure [10](#F10){ref-type="fig"}). In contrast, the protein was more widespread, with very dark and uniform immunoreactivity in the molecular layer. The granule cell layer presented VGLUT1-IR punctate labeling corresponding to mossy fiber terminals. Finally, white matter contained faintly stained cell bodies reminiscent of interstitial cells. Although VGLUT2 mRNA was not detected in the cerebellum, protein was found throughout this region, but with a distribution that differed markedly from that of VGLUT1. The granule cell layer displayed the strongest signal, with VGLUT2-IR confined to mossy fiber terminals. The fainter immunoreactivity in the molecular layer was limited to sparse varicose fibers. As for VGLUT3 neither its transcript nor the protein were detected in the cerebellum. None of the VGLUTs (mRNA or protein) were expressed in the Purkinje cells.

![**Distribution of VGLUT1-3 mRNA and protein (immunoautoradiography \[IAR\] and immunohistochemistry \[IHC\]) in the cerebellum**. Abbreviations: GcL, granular cell layer of the cerebellum; Mo, molecular layer of the cerebellum; Pc, Purkinje cell layer; Pk, Purkinje cell; wm, white mater.](fnana-09-00023-g0010){#F10}

Discussion {#s4}
==========

The anatomical distribution of VGLUTs has been thoroughly described in rodents (see for example, Ni et al., [@B34]; Bellocchio et al., [@B3], [@B4]; Aihara et al., [@B1]; Fremeau et al., [@B15], [@B13], [@B14],[@B16]; Gras et al., [@B19], [@B20], [@B18]; Kaneko and Fujiyama, [@B25]; Varoqui et al., [@B48]; Herzog et al., [@B22]; Hioki et al., [@B23]). However, only a few studies have been conducted in the human brain. Some of these studies analyzed the distribution of mRNA coding for VGLUTs (such as McCullumsmith and Meador-Woodruff, [@B30]; Oni-Orisan et al., [@B35]; Uezato et al., [@B46]; Van Der Hel et al., [@B47]); or investigated the presence of the proteins with subtype specific antisera (such as Kirvell et al., [@B28]; Kashani et al., [@B26], [@B27]; Oni-Orisan et al., [@B35]; Van Der Hel et al., [@B47]) in a few brain regions. The current study aimed at localizing mRNA and protein of all three VGLUTs in various regions of the human brain, using respectively *in situ* hybridization and immunoautoradiography with VGLUT subtype-specific antisera. For this purpose, we developed the first human anti-VGLUT3 antiserum. This new anti-VGLUT3 provided the exact same immunolabeling pattern in rodent brain as that of a previously validated anti-mouse VGLUT3 antibody (Gras et al., [@B18]; Amilhon et al., [@B2]; Miot et al., [@B31]). A further indication of this serum\'s specificity was that it immunolabeled identical brain regions in rodents and humans, as discussed below. Furthermore, no labeling was observed when this antiserum was used on sections from mice no longer expressing VGLUT3 (Gras et al., [@B18]; Amilhon et al., [@B2]). These results strongly suggest that the newly developed antisera specifically recognize VGLUT3 and not the closely related VGLUT1 or VGLUT2 subtypes.

Our results are in line and extend previously published results. We found that transcripts coding for VGLUT1 and VGLUT2 were easily visualized. Interestingly, VGLUT1 and VGLUT2 transcripts are absent from area where both proteins are abundantly expressed (such as the caudate-putamen for example). This mismatch has been previously reported in rodent (Herzog et al., [@B21]) and reflects the fact that vesicular glutamate transporters are targeted to presynaptic terminals of principal neurons.

In human brains, VGLUT3 mRNA was hardly detected in some areas given weak signals and the small numbers of cells synthesizing this transcript. In contrast to VGLUT1 and VGLUT2, VGLUT3 transcript is often colocalized with the protein (in the hippocampus or caudate-putamen for example). This result suggests that, VGLUT3 has a discrete distribution in the human brain, similar to that previously described in rodents (Gras et al., [@B19]; Herzog et al., [@B22]).

As in rodents (Herzog et al., [@B22]), VGLUT3 mRNA was absent from the thalamus, the substantia nigra and the cerebellum whereas it was detected in sparse cells in the cortex, hippocampus, caudate-putamen, and in a more concentrated cell population within the raphe. The distribution of VGLUT3 transcript strongly suggests a localization in GABAergic interneurons in cerebral cortex and hippocampus, and in cholinergic interneurons in the caudate-putamen. This indicates a highly conserved expression pattern between rodents and humans. In the raphe, the VGLUT3-positive cell population appeared to be intermingled with 5-HT neurons but not totally overlapping the distribution of SERT mRNA. Here again suggesting that, as in rodents, VGLUT3 is expressed in a subpopulation of 5-HT neurons (Kiyasova et al., [@B29]). However, double-labeling experiments will be required to fully confirm these hypotheses. In contrast to the mRNA, VGLUT3-IR signal was found throughout gray mater areas with the exception of the cerebellum and thalamic nuclei. Interestingly, in the cerebral cortex, VGLUT3 seems to be more abundantly present in layer I--III and V--VI. This immunolabeling pattern is also highly similar to the one reported in rodent brain (Herzog et al., [@B22]; Somogyi et al., [@B41]). This implies that VGLUT3 is likely involved in the regulation of locomotor activity, reward and mood in humans, as previously suggested by studies conducted on mutant mouse models (Seal and Edwards, [@B40]; Gras et al., [@B18]; Amilhon et al., [@B2]). Since VGLUT3 is very discretely distributed in the human brain, it is a likely candidate for targeted treatments of specific pathologies such as Parkinson\'s disease, addiction, or mood disorders.

VGLUT1 and VGLUT2 patterns of mRNA expression in human brains corresponded to prominent cortical and subcortical glutamatergic systems, as previously described in rodents. In cerebral cortex, VGLUT1 mRNA displayed the most intense VGLUT signal. It was concentrated in layers V-VI, and thus presumably associated with pyramidal neurons projecting to subcortical structures. VGLUT2 mRNA, however, was rather weakly expressed in cortex, with signal being limited to a small band of cells in the middle layers. In contrast, protein expression for both transporter subtypes was strong in cerebral cortex. VGLUT1-IR yielded the strongest and most uniform staining in neocortex, spanning all layers homogeneously. VGLUT2-IR was also found throughout the cortical thickness, but much more weakly, except for a dense IR band in mid-cortex that colocalized with its mRNA distribution. This band also likely corresponded to layer V pyramidal neurons. The combined intensities of VGLUT1- and VGLUT2-IR throughout the cortical thickness clearly reflects the abundance of cortical and subcortical glutamatergic axon terminating in this structure. In the hippocampus, VGLUT1 (but not VGLUT2) was also associated with projection neurons. VGLUT1 mRNA sharply outlined the CA fields as well as the dentate gyrus, with strong signal in pyramidal neurons as well as granule cells. Thus, as in rodents, VGLUT1- and VGLUT2-IR suggests that VGLUT1 is the major vesicular glutamate transporter in the hippocampus and that VGLUT2 has only a discrete distribution in this area.

In subcortical regions, VGLUT1 and VGLUT2 displayed variable expression patterns. In the basal ganglia, although mRNAs for these transporters were completely absent, VGLUT1- and VGLUT2-IR were very intense in the caudate, putamen as well as the nucleus accumbens, and moderate in the substantia nigra. As previously described in rodents, VGLUT2-IR in the globus pallidus was also of moderate intensity, whereas VGLUT1 was absent. In the amygdala, the basolateral amygdaloid complex was the only region strongly delineated by VGLUT1- and VGLUT2-IR, as well as by VGLUT1 mRNA expression. Of note was the particularly high VGLUT2 mRNA and protein expression in the habenular complex, and moderate VGLUT1-IR in the lateral habenula. The only VGLUT mRNA (weakly) expressed in the thalamus was that coding for VGLUT2, with proportionally moderate immunoreactivity. The latter was uneven at the anatomical level examined, with sharp differences between thalamic nuclei. Heterogeneous VGLUT1-IR was also observed between nuclei, but its distribution did not match that of VGLUT2-IR.

The only VGLUT mRNA detected in the cerebellum was VGLUT1 mRNA strongly expressed in but confined to the granule cell layer. VGLUT1 and VGLUT2 proteins, however, were abundantly expressed and presented a complementary distribution along cerebellar layers. This strong IR is thus mainly provided by cerebellar afferents, among which the pontine nucleus was found to express high levels of VGLUT1 and VGLUT2 mRNA.

Similar to rodents (Herzog et al., [@B22]), VGLUT3 mRNA was absent from the thalamus, the substantia nigra and the cerebellum whereas it was detected in sparse cells in the cortex, hippocampus, caudate-putamen, and in a more concentrated cell population within the raphe. The distribution of VGLUT3 transcript strongly suggests a localization in GABAergic interneurons in cerebral cortex and hippocampus, and in cholinergic interneurons in the caudate-putamen. Again, this indicates a highly conserved expression pattern between rodents and humans. In the raphe, the VGLUT3-positive cell population appeared to be intermingled with 5-HT neurons but not totally overlapping the distribution of SERT mRNA. Here again suggesting that, as in rodents, VGLUT3 is expressed in a subpopulation of 5-HT neurons. However, double-labeling experiments will be required to fully confirm this hypothesis. In contrast to the mRNA, VGLUT3-IR signal was found throughout gray mater areas with the exception of the cerebellum and thalamic nuclei. Interestingly, in the cerebral cortex, VGLUT3 seems to be more abundantly present in layer I--III and V--VI. This immunolabeling pattern is also highly similar to the one reported in rodent brain (Herzog et al., [@B22]).

In summary, the anatomical distributions of brain cells expressing each one of the 3 VGLUTs are strikingly different. In contrast, the proteins are often found within the same areas (with the exception of the cererbellum and the thalamus, in which VGLUT3 was not detected). The regional distributions of VGLUT transcripts and proteins was found to be highly similar between human and rodent, suggesting that these transporters play fundamental roles in brain function that were conserved with evolution. This knowledge is particularly important given the previous implication of VGLUTs in cerebral pathologies, as it validates the use of rodent models to uncover the molecular mechanisms underlying human mental illnesses.
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